Page last updated: 2024-12-05
allyl carbamate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16454 |
| SCHEMBL ID | 29564 |
| SCHEMBL ID | 9763314 |
| MeSH ID | M0106664 |
Synonyms (41)
| Synonym |
|---|
| allyl carbamate |
| nsc32609 |
| 2114-11-6 |
| carbamic acid, 2-propenyl ester |
| carbamic acid, allyl ester |
| wln: zvo2u1 |
| nsc-32609 |
| brn 1745069 |
| nsc 32609 |
| hsdb 2714 |
| nsc 63830 |
| einecs 218-309-6 |
| allylurethane |
| nsc63830 |
| nsc-63830 |
| prop-2-enyl carbamate |
| 4-03-00-00062 (beilstein handbook reference) |
| carbamic acid, 2-propen-1-yl ester |
| unii-imp2j1yj2y |
| imp2j1yj2y , |
| AKOS006222282 |
| allylurethane [hsdb] |
| SCHEMBL29564 |
| OCAAZRFBJBEVPS-UHFFFAOYSA-N |
| carbamic acid allyl ester |
| o-allyl carbamate |
| SCHEMBL9763314 |
| dtxcid4030413 |
| cas-2114-11-6 |
| dtxsid1051856 , |
| NCGC00357158-01 |
| tox21_303906 |
| allyl carbamate, 95% |
| EN300-210216 |
| prop-2-en-1-yl carbamate |
| mfcd00025468 |
| Q27280799 |
| D97550 |
| prop-2-en-1-ylcarbamate |
| AS-76151 |
| CS-0199028 |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.17
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.17) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||